INTRODUCTION {#s1}
============

Atrial fibrillation is the most common clinically relevant arrhythmia \[[@R01]\], and its management is based on rate control \[[@R02]\], and antithrombotic therapy \[[@R03]\]. Stroke and systemic embolism are the most feared complications of atrial fibrillation. Warfarin and other oral vitamin K antagonists have been proved effective and relatively safe in the prevention of thromboembolic risk of patients without bleeding diathesis but at moderate or high risk of stroke \[[@R04]\].

Warfarin has several limitations \[[@R01]\]. First, it has a narrow therapeutic window and requires frequent monitoring of the international normalized ratio (INR). In addition, it has highly variable response \[[@R05]\], as well as multiple drug and food interactions \[[@R06]\]. Finally, despite optimal warfarin treatment, thromboembolic events still occur in several patients \[[@R07],[@R08]\].

Novel oral anticoagulants have been recently developed and formally tested in warfarin-controlled phase III randomized trials \[[@R09],[@R10],[@R11]\], and others are currently completing pivotal trials \[[@R12],[@R13],[@R14]\]. Specifically, apixaban (Eliquis; Bristol-Myers Squibb and Pfizer), edoxaban (Lixiana, Daiichi Sankyo and Eli Lilly) and rivaroxaban (Xarelto; Bayer and Johnson & Johnson) are oral direct Factor Xa (FXa) inhibitors, whereas dabigatran etexilate (Pradaxa, Pradax or Prazaxa; Boehringer Ingelheim) is an oral prodrug which is converted by plasma and hepatic esterases to dabigatran, a direct Factor IIa (FIIa, i.e. thrombin) inhibitor (*Table 1*) \[[@R15]\].

![Pharmacokinetics of the novel oral anticoagulants.](hsrp-05-040-g001){#F001}

Promising data have been reported for all such novel drugs when compared to warfarin in patients with atrial fibrillation, yet it is unclear whether they do really represent a favorable breakthrough in the management of atrial fibrillation. In addition, the practicing physician remains uncertain about the relative strengths and weaknesses of each of these new treatment options as no direct comparison among them is available nor is foreseeable in the next future.

Network meta-analyses, as mixed treatment comparisons, are novel research designs capable of comparing different treatments exploiting common comparators, and their role in clinical research and practice has already been established \[[@R16]\]. Whereas other network meta-analyses have already been reported focusing on dabigatran and antiplatelet therapy \[[@R17],[@R18]\], no study is available comparing novel oral anticoagulants for atrial fibrillation.

We thus aimed to perform pair-wise and warfarin-controlled network meta-analyses of novel oral anticoagulants for atrial fibrillation.

METHODS {#s3}
=======

*Design and registration.* The present review was performed according to the Cochrane Collaboration and PRISMA statements \[[@R19],[@R20]\]. In addition, it was prospectively registered on metcardio.org (protocol \#3/2010).

Search. MEDLINE/PubMed was searched according to this highly sensitive strategy, modified by Biondi-Zoccai et al \[[@R21]\], on September 10, 2011: (apixaban OR rivaroxaban OR dabigatran OR (novel AND oral AND anticoagulant\*)) AND atrial AND fibrillation AND (randomized controlled trial\[pt\] OR controlled clinical trial\[pt\] OR randomized controlled trials\[mh\] OR random allocation\[mh\] OR double-blind method\[mh\] OR single-blind method\[mh\] OR clinical trial\[pt\] OR clinical trials\[mh\] OR (clinical trial\[tw\] OR ((singl\*\[tw\] OR doubl\*\[tw\] OR trebl\*\[tw\] OR tripl\*\[tw\]) AND (mask\*\[tw\] OR blind\[tw\])) OR (latin square\[tw\]) OR placebos\[mh\] OR placebo\*\[tw\] OR random\*\[tw\] OR research design\[mh:noexp\] OR follow-up studies\[mh\] OR prospective studies\[mh\] OR cross-over studies\[mh\] OR control\*\[tw\] OR prospectiv\*\[tw\] OR volunteer\*\[tw\]) NOT (animal\[mh\] NOT human\[mh\]) NOT (comment\[pt\] OR editorial\[pt\] OR meta-analysis\[pt\] OR practice-guideline\[pt\] OR review\[pt\])). In addition, Google Scholar, The Cochrane Library, and Scopus were also searched for pertinent citations.

References of retrieved studies were checked for additional studies (backward snowballing) and 2008-2011 conference proceedings of the American College of Cardiology, American Heart Association, and European Society of Cardiology scientific sessions were also manually searched. No language restriction was enforced.

*Selection.* Study selection was performed by two independent reviewers (GBZ, ML), with divergences resolved by consensus. Citations were first scanned at the title/abstract level. Shortlisted studies were then retrieved in full text.

They were considered suitable for inclusion if: reporting on randomized trials, comparing warfarin versus novel oral anticoagulants, enrolling patients with atrial fibrillation (all the criteria had to be satisfied for inclusion). Studies were excluded if non-randomized, used other controls than warfarin, included patients without atrial fibrillation, or focused on ximelagatran/melagatran, which is no longer developed given severe liver toxicity \[[@R22]\].

*Abstraction and appraisal.*Data abstraction and study appraisal were performed by two independent reviewers (GBZ, ML), with divergences resolved by consensus. Key study and patient characteristics were extracted, including the following outcomes, reported at the longest available follow-up according to intention-to-treat principles:

stroke or systemic embolism (primary end-point);all-cause death;major bleeding defined according to the Thrombolysis in Myocardial Infarction (TIMI) definition;drug discontinuation. 

In addition, study validity was appraised according to the risk of bias tool recommended by The Cochrane Collaboration \[[@R23]\]. All corresponding authors of shortlisted studies were directly contacted for data quality and completeness.

*Analysis.* Categorical variables are reported as events/patients at risk and were compared with odds ratios (OR) with 95% confidence/credible intervals. Overall pair-wise meta-analyses were performed with DerSimonian-Laird method and random-effect model by means of RevMan 5.0.24 (The Cochrane Collaboration, Copenhagen, Denmark), checking statistical consistency by means of I^2^ \[[@R24]\].

In addition, small study effects were appraised by visual inspection of funnel plots. Notably, no formal test for publication bias was used given the few included studies and variable comparators included. Subsequently, warfarin-adjusted network meta-analyses (actually indirect treatment comparisons, given the star-shaped network) were performed using a fixed-effect model with WinBUGS 1.4.3, which behaves similarly to an indirect comparison method given the star shape. Each analysis was based on non-informative priors for effect sizes. Convergence and lack of auto-correlation were checked and confirmed after a 100,000-simulation burn-in phase, and, finally, direct probability statements were based on an additional 500,000-simulation phase. Deviance and deviance information criterion (DIC) were used to appraise model fit in comparison to a random-effect model. Comparisons are presented throughout using warfarin as reference treatment and ordering experimental treatments alphabetically.

 

 

RESULTS {#s4}
=======

*Studies.* From a total of 7114 citations, 7 trials were finally included (*Tables 2-6*).
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![Risk of bias assessment of included studies.](hsrp-05-040-g005){#F005}
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Specifically, two trials focused on apixaban \[[@R10],[@R25]\], two trials focused on dabigatran at variable dosages \[[@R09],[@R26]\], two trials focused on edoxaban at variable dosages \[[@R12],[@R13]\], and one trial focused on rivaroxaban (Tables 2-4) \[[@R11]\].

All included studies were randomized clinical trials, varying from small phase II dose-finding studies \[[@R12],[@R13],[@R25],[@R26]\], from large phase III pivotal studies with a non-inferiority scope \[[@R09],[@R11]\]. Inclusion and exclusion criteria were largely similar, but patients enrolled in the ROCKET AF trial of rivaroxaban versus warfarin had a higher prevalence of adverse clinical features, including a higher CHADS2 score (*Tables 2-4*).

Despite this, enrolment criteria were sufficiently homogeneous (i.e. all studies included patients in whom warfarin was considered beneficial) to ensure that the key assumption of any network meta-analysis (namely the focus on a common patient subset treated with the same comparator) hold true. The internal validity of included studies was high, especially given the logistical challenges involved in the conduct of a double-blind trial when warfarin is the control treatment (*Table 5*).

*Pair-wise meta-analysis.* First, we conducted a standard pair-wise meta-analysis pooling all novel oral anticoagulants together and comparing them against warfarin performing a random-effect model. After a weighted average follow-up of 23 months, novel oral anticoagulants were associated with significant reductions in the risk of stroke or systemic embolism (OR=0.81 \[0.71-0.92\], I^2^=23%) all cause death (OR=0.88 \[0.82-0.95\], I^2^=0%), in comparison to warfarin, with a favorable trend for major bleeding (OR=0.83 \[0.68-1.02\], I^2^=73%). Conversely, aggregate analysis showed a similar or slightly increased risk of study drug discontinuation with novel oral anticoagulants (OR=1.18 \[0.96-1.46\], I^2^=92%) versus warfarin. However, both estimates regarding major bleeding and drug discontinuation were statistically inconsistent, suggesting different effects of the different anticoagulants. Funnel plot inspection suggested the presence of small study effects due to the inclusion of phase II trials with a small sample size. However, sensitivity analysis excluding all studies with sample size ≤5,000 patients confirmed in magnitude and direction our overall findings.

*Network meta-analysis.* Warfarin-controlled network meta-analysis enabled the head-to-head comparison of each novel oral anticoagulant against warfarin as well as against each other individual drug (*Table 7*).

![Clinical outcomes in included studies\*.](hsrp-05-040-g007){#F007}

After a weighted average follow-up of 23 months, apixaban and high-dose dabigatran proved similarly effective in preventing stroke or systemic embolism in comparison to warfarin (OR=0.78 \[0.62-0.96\] for apixaban and OR=0.66 \[0.52-0.84\] for high-dose dabigatran vs warfarin; indirect OR of apixaban versus high-dose dabigatran=1.17 \[0.85-1.63\]). However, apixaban was associated with fewer major bleedings than high-dose dabigatran (OR=0.73 \[0.57-0.93\]) and fewer drug discontinuations than either high-dose dabigatran (OR=0.64 \[0.52-0.78\]) or low-dose dabigatran (OR=0.66 \[0.54-0.81\]).

Low-dose dabigatran was associated with fewer major bleedings than warfarin (OR=0.80 \[0.66-0.97\]), but was discontinued more frequently (OR=1.36 \[1.16-1.58\]) than the older agent. Conversely, rivaroxaban did not appear to reduce the risk of stroke or systemic embolism (OR=0.87 \[0.71-1.07\]) or major bleeding incomparison to warfarin (OR=0.87 \[0.71-1.07\]) and was associated with credibly more major bleedings in comparison to apixaban (OR=1.52 \[1.19-1.92\]).

Data for edoxaban were largely inconclusive, as the pertinent phase III pivotal trial is still ongoing (i.e. ENGAGE AF-TIMI 48). Nonetheless, high-dose edoxaban was discontinued more frequently than warfarin (OR=5.29 \[1.15-49.7\]), apixaban (OR=5.89 \[1.28-50.1\]) and rivaroxaban (OR=4.76 \[1.05-4.76\]).

DISCUSSION {#s7}
==========

This systematic review provides direct evidence that novel oral anticoagulants represent a paradigm shift in the management of atrial fibrillation, as they are associated with significant benefits on the risk of stroke or systemic embolism and death. In addition, by exploiting the use of warfarin as a common comparator within the framework of a network meta-analysis, this study shows that both apixaban and high-dose dabigatran are superior to warfarin for the prevention of thromboembolism with a similar efficacy, and that apixaban appears to be better tolerated and associated with reduced bleeding when compared with dabigatran.

Apixaban is an inhibitor of coagulation factor Xa, orally bioavailable and mostly metabolized by the hepatic CYP3A4 system \[[@R15],[@R27]\]. The recommended dose is 5 mg twice daily but the dose is to be reduced with renal impairment. The use of apixaban is discouraged in patients with severe liver disease, and caution should be used when CYP3A4 or P-glycoprotein inhibitors or inducers are used concomitantly. As for all factor Xa inhibitors routine monitoring of efficacy is not available, as anti-Xa activity may determined but it is often not available. To date, no specific antidote to reverse the effects of apixaban is known. The superior efficacy in preventing thromboembolism associated with a reduction in major bleeding when compared with warfarin suggest that in patients without contraindications, apixaban is preferable to warfarin. The indirect comparisons of apixaban with the other oral anticoagulants dabigatran, edoxaban, and rivaroxaban, show that efficacy of apixaban in preventing thromboembolism is not statistically different from the others. A numerically higher risk of thromboembolism was seen for apixaban in comparison with high-dose dabigatran (OR=1.17), high-dose edoxaban (OR=3.70) and low-dose edoxaban (OR=1.43), but for all these cases the confidence interval largely crossed the unity meaning that the difference was not statistically credible, for which the superiority of these agents in comparison with apixaban could not be proven (nor negated). In terms of safety, apixaban was associated with significantly fewer major bleeding episodes when compared with warfarin, high-dose dabigatran and rivaroxaban (ORs between 0.66 and 0.73) and no significant differences compared with low-dose dabigatran or edoxaban with all ORs crossing the unity.

Dabigatran, on the other hand, is a coagulation factor IIa (thrombin) inhibitor \[[@R15],[@R28]\]. Dabigatran etexilate is orally bioavailable and rapidly converted in dabigatran under the effects of plasma and hepatic esterases. Dabigatran is cleared by the kidney, and the dose recommended by the Food and Drug Administration is 150 mg twice daily for creatinine clearance \>30 ml/min\*m^2^, with the dose reduced to 75 mg twice daily for creatinine clearance ≤30 ml/min\*m^2^, whereas its use it not recommended for lower creatinine clearance (i.e. ≤15 ml/min\*m^2^). At odds with apixaban, dabigatran is not metabolized by the liver and it has no drug-to-drug interaction with CYP3A4 inhibitors or inducers, whereas it still interacts with P-glycoprotein inhibitors or inducers. Dabigatran affects both activated partial thromboblastin and ecarin clotting times, but routine monitoring of efficacy is not indicated. Like apixaban, no specific antidote to reverse the effects of dabigatran is known.

The RELY trial appraised also the 110 mg twice daily dose (low-dose) of dabigatran which is not approved for clinical use in the US but only in Europe \[[@R09]\]. In this study, in which randomization to dabigatran (one of two doses) or warfarin was open label, high-dose dabigatran showed greater efficacy in prevention of thromboembolism and a similar effect on major bleeding. These effects were associated with an important reduction by dabigatran in intracranial bleeding and a significant increase in gastrointestinal bleeding with dabigatran when compared with warfarin. Moreover, dabigatran was associated with a higher discontinuation rate than warfarin. In the indirect analyses, when compared with apixaban, dabigatran showed a similar efficacy in the prevention of thromboembolism (OR 1.17 \[0.85-1.63\] favoring dabigatran) but a credibly higher rate of major bleeding or discontinuation. Considering these factors, in the absence of contraindications, apixaban may appear superior to dabigatran. Special conditions such as the presence of liver impairment or concomitant use of CYP34A inhibitors or inducers may however prevent the use of apixaban and not of dabigatran. Additional head-to-head studies sufficiently powered to directly compare efficacy of the 2 drugs are needed, but unlikely to be available in the next 4-6 years. Notably, apixaban and dabigatran are both approved for the use in patients with non-valvular atrial fibrillation in the USA, whereas edoxaban and rivaroxaban are not. The European Medicines Agency has already approved both 110 mg and 150 mg twice daily regimens of dabigatran, but has not yet approved other novel oral anticoagulants for the treatment of atrial fibrillation.

Edoxaban is an additional factor Xa inhibitor that has been studied in a smaller number of patients \[[@R14],[@R15]\]. It is also orally bioavailable, it has renal clearance and minor hepatic metabolism. Data on efficacy and safety are however limited, awaiting the pertinent phase III pivotal trial (ENGAGE-TIMI 48) \[[@R14]\].

Rivaroxaban is another factor Xa inhibitor which is orally bioavailable, metabolized by liver and kidney \[[@R15],[@R29]\].The dose used in the large ROCKET-AF study was 20 mg daily (to be reduced to 15 mg if creatinine clearance between 30-49 ml/min\*m^2^). Like apixaban, it interacts with CYP3A4 or P-glycoprotein inhibitors and inducers, and should not be used in patients with advanced liver disease. As for all factor Xa inhibitors routine monitoring of efficacy is not available, as anti-Xa activity may be determined but it is uncommonly used. In the ROCKET-AF trial, rivaroxaban was shown to be non-inferior to warfarin in terms of thromboembolism or stroke. In this indirect comparison, rivaroxaban appeared to have similar efficacy in preventing thromboembolism when compared with the apixaban and dabigatran but was associated with significantly greater bleeding compared with apixaban. The once daily administration schedule may appear favorable to patient compliance as compared with apixaban and dabigatran, but the superior efficacy of apixaban and dabigatran, and greater safety of apixaban make rivaroxaban a less favorable choice. There is no specific antidote for rivaroxaban, however, a recent report described full reversibility of rivaroxaban effects (but not of dabigatran effects) with protrombin complex concentrate \[[@R30]\].

If confirmed in additional studies which would need to include also a determination of the effects of prothrombin complex concentrate on apixaban, this may support the use of rivaroxaban in settings in which need for rapid reversal may be anticipated.

The lack of requirement for monitoring with these agents has been viewed mostly as an advantage, but it can clearly represent a disadvantage when non-compliance with therapy or overdose is suspected. The wide-spread availability of INR monitoring for warfarin use has been advocated as a reason to prefer warfarin to these new anticoagulants, however, the lack of reduced bleeding with warfarin and INR monitoring in comparison with the use of these agents without monitoring argues that the availability of INR monitoring is not a sufficient reason to advocate for warfarin.

The lack of an antidote for the new agents has also been viewed as a limitation, and it certainly is. However the same holds true for warfarin considering that vitamin K is a slow acting antidote and is likely to reverse the effects of warfarin in the same time needed for any of these new agents to revert their effects without antidote.

In addition, direct costs will be much higher with these new agents than with warfarin. Whereas a cost-benefit or cost-utility analysis was of course beyond our scope, we can provide some informed speculations. First, warfarin costs are very low if we focus only on the cost of the pill itself, but if we add the indirect yet remarkable costs of dedicated INR monitoring centers, days off work to get blood draws, and, most importantly, the cost of recurrent thromboses and bleeding complications, then a warfarin regimen does not appear as economically appealing as it initially seemed. Moreover, taking for granted the reduction in the risk of death with novel oral anticoagulants, which is a rather uncommon finding in the realm of thromboembolism management, we should ask ourselves whether it is ethically sound to deny this drugs to any patient suitable for such life-saving therapy. More practically, we may anticipate that uptake of these new drugs will be slow, yet progressively increase. It can also be conceived that these drugs might be cost-saving (thus proving cheaper than warfarin) in those intolerant to warfarin or failing warfarin (i.e. experiencing a thromboembolic events despite adequate INR). Conversely, we might expect novel oral anticoagulants to be reasonable cost-effective (thus associated with a socially acceptable premium price), in patients at moderate to high thromboembolic risk and concomitantly at moderate to high bleeding risk with warfarin. It is unclear what cost analyses will show in other patient subsets. Thus, further detailed analyses, including also real-world patients (typically excluded from pivotal randomized trials) are warranted.

Finally, the unprecedented reduction in mortality with novel oral anticoagulants might appear surprising. Awaiting for further sub-analyses of the included trials, we may suggest a number of explanations for this finding. First, novel oral anticoagulant might prove life-saving because they maintain more often the patient in the correct therapeutic window. This means fewer thromboembolic episodes as well as fewer bleedings, both of which might be fatal if very severe or occurring in very sensible organs or systems. In addition, novel oral anticoagulants might be suitable for more patients than warfarin alone, and thus treat adequately a subset of patient who otherwise discontinue or are never treated with warfarin. Finally, we cannot exclude pleiotropic effects, such as those provided, in a very different context, by statins. However, much more clinical and pathophysiologic studies are required before considering the life-saving properties of novel oral anticoagulants as a given fact.

***Limitations***

Drawbacks of meta-analyses in general are well known, and additional limitations of network meta-analyses can be envisioned \[[@R31],[@R32],[@R33]\]. Nonetheless, we emphasize that clinical decision making is often based on incomplete evidence, and large head-to-head randomized trials of novel oral anticoagulants for atrial fibrillation do not exist and are not foreseeable for the next 4-6 years, at least. Indeed, we remain positive that network meta-analyses based on indirect comparisons are exquisitely scientific, as they inform on what will be the outcomes of future randomized clinical trials, and thus are uniquely falsifiable, in keeping with Popper's theories \[[@R34]\]. In addition, we decided a priori to exclude studies, remote or recent, enrolling patients unsuitable for warfarin therapy such as those candidates to low-dose aspirin \[[@R35]\], clopidogrel \[[@R36]\], or left atrial appendage closure \[[@R37]\], under the assumption that these subjectes were unlikely to have a risk-benefit profile similar to those suitable for long-term warfarin therapy. Yet, this focus on warfarin-eligibile patients limited the scope of the present network meta-analysis. In addition, data on edoxaban were limited, and thus results on this specific agent should be mainly considered hypothesis-generating. Other drawbacks of our work include the focus on 4 end-points only. Specifically, we did not explore in detail reasons for drug discontinuation (e.g. dyspepsia for dabigatran) nor causes for death (e.g. myocardial infarction) or type of bleeding (e.g. intracranial versus gastrointestinal). Further confirmatory analyses, beyond indirect comparisons \[[@R38],[@R39],[@R40],[@R41],[@R42],[@R43]\], are warranted for these important details, but are beyond the scope of the this review.

CONCLUSION {#s8}
==========

Novel oral anticoagulants represent a paradigm shift in the management of non-valvular atrial fibrillation. This study shows that both apixaban and dabigatran (150 mg) are superior to warfarin for the prevention of thromboembolism with a similar efficacy, and that apixaban appears to be better tolerated and associated with reduced bleeding when compared with dabigatran. Considering that 'one size' may not fit all patients, apixaban may represent the preferred agent for the majority of patients with non-valvular atrial fibrillation. Dabigatran may be considered for patients who are not candidates for apixaban. Rivaroxaban may be a less favorable choice in comparison to apixaban or dabigatran whereas it remains a valid alternative to warfarin. The data on edoxaban is to date inconclusive. Given the superiority in one or more aspects (efficacy, safety, ease-of-use), warfarin should not remain first choice of anticoagulation in patients with non-valvular atrial fibrillation and at least moderate thromboembolic risk.
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